Remove Biobanking Remove Development Remove Genome Project
article thumbnail

Can genetic data be a magic bullet for drug R&D?

pharmaphorum

Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments. Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates.

article thumbnail

Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data

The Pharma Data

to build a scalable data, analytics, and infrastructure platform This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine. Boehringer Ingelheim partners with Lifebit Biotech, Ltd.

article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

The combination of advanced long- and short-read genomic sequencing technologies holds great promise for precision oncology, and in the development of mRNA vaccines for certain cancers. With its already strong genomics foundation, the passing of this bill will cement the UK as a world leader in genomics.

Genome 129